Preferred Name

Cabozantinib S-malate
Synonyms
Definitions

The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

ID

http://purl.obolibrary.org/obo/NCIT_C97938

Accepted_Therapeutic_Use_For

advanced renal cell carcinoma (RCC); hepatocellular carcinoma (HCC)

CAS_Registry

1140909-48-3

Chemical_Formula

C28H24FN3O5.C4H6O5

code

C97938

Contributing_Source

CTRP

FDA

definition

The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

Display_Name

Cabozantinib S-malate

FDA_UNII_Code

DR7ST46X58

Has_Free_Acid_Or_Base_Form

http://purl.obolibrary.org/obo/NCIT_C52200

Has_Target

http://purl.obolibrary.org/obo/NCIT_C26203

http://purl.obolibrary.org/obo/NCIT_C17475

http://purl.obolibrary.org/obo/NCIT_C18539

http://purl.obolibrary.org/obo/NCIT_C18488

http://purl.obolibrary.org/obo/NCIT_C17328

http://purl.obolibrary.org/obo/NCIT_C26202

http://purl.obolibrary.org/obo/NCIT_C18186

http://purl.obolibrary.org/obo/NCIT_C17975

http://purl.obolibrary.org/obo/NCIT_C28496

http://purl.obolibrary.org/obo/NCIT_C33983

in_subset

http://purl.obolibrary.org/obo/NCIT_C63923

http://purl.obolibrary.org/obo/NCIT_C177537

http://purl.obolibrary.org/obo/NCIT_C176424

http://purl.obolibrary.org/obo/NCIT_C116977

http://purl.obolibrary.org/obo/NCIT_C116978

http://purl.obolibrary.org/obo/NCIT_C128784

http://purl.obolibrary.org/obo/NCIT_C157711

http://purl.obolibrary.org/obo/NCIT_C157712

Is_Value_For_GDC_Property

http://purl.obolibrary.org/obo/NCIT_C1909

label

Cabozantinib S-malate

Maps_To

Cabozantinib S-malate

NCI_Drug_Dictionary_ID

461103

PDQ_Closed_Trial_Search_ID

461103

PDQ_Open_Trial_Search_ID

461103

Preferred_Name

Cabozantinib S-malate

prefixIRI

NCIT:C97938

prefLabel

Cabozantinib S-malate

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C3468008

subClassOf

http://purl.obolibrary.org/obo/NCIT_C93259

http://purl.obolibrary.org/obo/NCIT_C159438

http://purl.obolibrary.org/obo/NCIT_C143099

Delete Subject Author Type Created
No notes to display